Old Web
English
Sign In
Acemap
>
authorDetail
>
R. Deporte
R. Deporte
Breast cancer
Pathology
Regimen
Chemotherapy
Medicine
4
Papers
93
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Capecitabine + epirubicin + cyclophosphamide (CEX) has comparable safety to 5-FU + epirubicin + cyclophosphamide (FEC) as neoadjuvant therapy in patients (pts) with operable breast cancer (BC): Early safety findings from a randomized phase III trial
2006
Journal of Clinical Oncology
Henri Roché
R. Deporte
D. Berton Rigaud
B. Coudert
N. Tubiana-Mathieu
Jean-Marc Ferrero
H. Orfeuvre
Bruno Audhuy
L. Bobadilla
P. Fumoleau
Show All
Source
Cite
Save
Citations (3)
Establishment of a predictive classifier of node-positive breast cancer patients treated by FEC100 chemotherapy using gene expression profiling
2006
Journal of Clinical Oncology
Mario Campone
Catherine Charbonnel
Florence Magrangeas
Stephane Minvielle
Jean Genève
Anne-Laure Martin
R. Deporte
Régis Bataille
L. Campion
Pascal Jézéquel
Show All
Source
Cite
Save
Citations (0)
High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.
2006
Journal of Chromatography B
R. Deporte
M. Amiand
A. Moreau
C. Charbonnel
L. Campion
Show All
Source
Cite
Save
Citations (35)
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis
2004
British Journal of Cancer
Pascal Jézéquel
L. Campion
Marie-Pierre Joalland
M. Millour
F. Dravet
J.M. Classe
Valerie Delecroix
R. Deporte
P. Fumoleau
Gabriel Ricolleau
Show All
Source
Cite
Save
Citations (55)
1